Cover Image
市場調查報告書

末稍血管栓塞保護裝置:開發平台分析

Peripheral Embolic Protection Devices - Medical Devices Pipeline Assessment, 2016

出版商 GlobalData 商品編碼 338378
出版日期 內容資訊 英文 87 Pages
訂單完成後即時交付
價格
Back to Top
末稍血管栓塞保護裝置:開發平台分析 Peripheral Embolic Protection Devices - Medical Devices Pipeline Assessment, 2016
出版日期: 2016年11月01日 內容資訊: 英文 87 Pages
簡介

本報告提供全球各國的企業·醫療機關等開發中的末稍血管栓塞保護裝置之開發中產品資訊相關分析,提供您臨床實驗/產品開發的整體進展,及各階段·各領域·各地區的詳細趨勢,各企業·各產品的詳細資訊 (臨床實驗的進展階段,開始/結束時期,認證預測等),近來的產品開發動向·產業趨勢等資料,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 末稍血管栓塞保護裝置概要

第3章 開發中的產品

  • 開發中產品:各開發階段
  • 開發中產品:各部門
  • 開發中產品:各地區
  • 開發中產品:法規各途徑
  • 開發中產品:認證各時期 (估計)
  • 現在進行中的臨床實驗

第4章 末稍血管栓塞保護裝置:開發中的開發中產品 (各企業)

  • 末稍血管栓塞保護裝置的開發企業:開發中產品 (各開發階段)
  • 末稍血管栓塞保護裝置:各開發階段的開發中產品一覽

第5章 末稍血管栓塞保護裝置的開發企業·產品概要

  • Abbott Vascular Inc.
    • 開發中產品及進行中的臨床實驗概要
  • AngioDynamics, Inc.
  • Cardio-Flow Ltd.
  • CardioGard Ltd.
  • CardioLogical Solutions
  • Claret Medical, Inc.
  • Gardia Medical Ltd.
  • Innovative Cardiovascular Solutions, LLC
  • Innovia LLC
  • Keystone Heart Ltd.
  • Medtronic plc
  • Metactive Medical, LLC
  • MIV Therapeutics Inc
  • NeuroInterventions
  • Neurosonix Ltd.
  • Nexeon MedSystems, Inc.
  • Palmaz Scientific, Inc.
  • Trinity College Dublin
  • University of Minnesota
  • University of Toledo

第6章 末稍血管栓塞保護裝置:近來的市場趨勢

第7章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0240EPD

GlobalData's Medical Devices sector report, "Peripheral Embolic Protection Devices - Medical Devices Pipeline Assessment, 2016" provides an overview of Peripheral Embolic Protection Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Peripheral Embolic Protection Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Peripheral Embolic Protection Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Peripheral Embolic Protection Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Peripheral Embolic Protection Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Peripheral Embolic Protection Devices Overview

3. Products under Development

  • 3.1. Peripheral Embolic Protection Devices - Pipeline Products by Stage of Development
  • 3.2. Peripheral Embolic Protection Devices - Pipeline Products by Segment
  • 3.3. Peripheral Embolic Protection Devices - Pipeline Products by Territory
  • 3.4. Peripheral Embolic Protection Devices - Pipeline Products by Regulatory Path
  • 3.5. Peripheral Embolic Protection Devices - Pipeline Products by Estimated Approval Date
  • 3.6. Peripheral Embolic Protection Devices - Ongoing Clinical Trials

4. Peripheral Embolic Protection Devices - Pipeline Products under Development by Companies

  • 4.1. Peripheral Embolic Protection Devices Companies - Pipeline Products by Stage of Development
  • 4.2. Peripheral Embolic Protection Devices - Pipeline Products by Stage of Development

5. Peripheral Embolic Protection Devices Companies and Product Overview

  • 5.1. Abbott Vascular Inc. Company Overview
    • 5.1.1. Abbott Vascular Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.2. Avantec Vascular Corporation Company Overview
    • 5.2.1. Avantec Vascular Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.3. Cardio-Flow Ltd. Company Overview
    • 5.3.1. Cardio-Flow Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.4. CardioGard Ltd. Company Overview
    • 5.4.1. CardioGard Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.5. Claret Medical, Inc. Company Overview
    • 5.5.1. Claret Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.6. EKOS Corporation Company Overview
    • 5.6.1. EKOS Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.7. EMBA Medical Limited Company Overview
    • 5.7.1. EMBA Medical Limited Pipeline Products & Ongoing Clinical Trials Overview
  • 5.8. Inari Medical, Inc. Company Overview
    • 5.8.1. Inari Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.9. Innovative Cardiovascular Solutions, LLC Company Overview
    • 5.9.1. Innovative Cardiovascular Solutions, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.10. Innovia LLC Company Overview
    • 5.10.1. Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.11. Keystone Heart Ltd. Company Overview
    • 5.11.1. Keystone Heart Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.12. Medtronic plc Company Overview
    • 5.12.1. Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.13. Metactive Medical, LLC Company Overview
    • 5.13.1. Metactive Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.14. MIV Therapeutics Inc Company Overview
    • 5.14.1. MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.15. Neurosonix Ltd. Company Overview
    • 5.15.1. Neurosonix Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.16. Trinity College Dublin Company Overview
    • 5.16.1. Trinity College Dublin Pipeline Products & Ongoing Clinical Trials Overview
  • 5.17. University of Minnesota Company Overview
    • 5.17.1. University of Minnesota Pipeline Products & Ongoing Clinical Trials Overview
  • 5.18. University of Toledo Company Overview
    • 5.18.1. University of Toledo Pipeline Products & Ongoing Clinical Trials Overview

6. Peripheral Embolic Protection Devices- Recent Developments

  • 6.1. Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer
  • 6.2. Oct 05, 2016: AngioDynamics Reports Fiscal 2017 First Quarter Results
  • 6.3. Oct 03, 2016: American Journal of Cardiology Reports Data Showing New Brain Lesions in 94% of Patients Following TAVR
  • 6.4. Sep 20, 2016: Claret Medical Submits Marketing Application to FDA for US Clearance of First Cerebral Protection System for Transcatheter Aortic Valve Replacement (TAVR)
  • 6.5. Sep 19, 2016: TriGuard Cerebral Protection Device Demonstrates Safety and Significant Improvements in Brain Protection in Patients Undergoing TAVR Procedures
  • 6.6. Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services
  • 6.7. Sep 14, 2016: Claret Medical Announces SENTINEL Pivotal IDE Trial to Be Featured in Late-Breaking Trial Session at Transcatheter Cardiovascular Therapeutics (TCT) Conference
  • 6.8. Aug 30, 2016: MPSC Announces 2016 Interim Results
  • 6.9. Aug 25, 2016: Medtronic Reports First Quarter Financial Results
  • 6.10. Aug 09, 2016: Penumbra Reports Second Quarter 2016 Financial Results
  • 6.11. Aug 01, 2016: AngioDynamics to Raise Funds through Public Offering of Shares
  • 6.12. Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 2016
  • 6.13. Jul 26, 2016: Edwards Lifesciences Reports Second Quarter Results
  • 6.14. Jul 25, 2016: AngioDynamics Appoints Michael C. Greiner as New Chief Financial Officer
  • 6.15. Jul 13, 2016: Boston Scientific Elects Yoshiaki Fujimori to Board of Directors
  • 6.16. Jul 13, 2016: AngioDynamics Reports Fiscal 2016 Fourth Quarter and Full Year Results
  • 6.17. Jun 30, 2016: NuVasive Agrees to Settle Patent Litigation With Medtronic
  • 6.18. Jun 15, 2016: Keystone Heart Announces First Patient Enrolled in New Study to Protect the Brain During TAVR
  • 6.19. Jun 08, 2016: Boston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation
  • 6.20. Jun 06, 2016: Medtronic Outlines Future Growth Vision at Investor Day
  • 6.21. May 31, 2016: Medtronic Reports Fourth Quarter and Fiscal Year 2016 Financial Results
  • 6.22. May 31, 2016: Keystone Heart Appoints New President and Chief Executive Officer
  • 6.23. May 19, 2016: TriGuard Cerebral Protection Device Shows Reduction in Stroke Rate and Improvement in Patients' Neurological Outcomes in TAVR Procedures
  • 6.24. May 09, 2016: Penumbra Reports First Quarter 2016 Financial Results
  • 6.25. Apr 07, 2016: AngioDynamics Reports Fiscal 2016 Third Quarter Results
  • 6.26. Mar 31, 2016: Penumbra to Present Final Results of Multicenter Prism Trial on Indigo System at SIR 2016
  • 6.27. Mar 23, 2016: MicroPort Signs Cooperation Agreement with Beijing Weimai Medical Device
  • 6.28. Mar 08, 2016: Inari Medical Announces IDE Approval To Study The Flowtriever System For The Treatment Of Pulmonary Embolism
  • 6.29. Feb 02, 2016: EndoShape Raises USD7 Million in Venture Financing
  • 6.30. Jan 06, 2016: Penumbra Introduces POD Packing Coil for the Embolization of Peripheral Vessels and Aneurysms
  • 6.31. Dec 28, 2015: Registration of Dongguan Kewei Occluder Series Products in Kazakhstan Approved
  • 6.32. Dec 23, 2015: MicroPort Completed the First Distant Interactive Surgery in the Field of Coronary Interventional Treatment
  • 6.33. Dec 02, 2015: MicroPort Orthopedics Attend the Tenth Session of the COA International Conference
  • 6.34. Nov 23, 2015: Inari Medical And Inceptus Medical Announce Receipt Of TCT Innovation Award
  • 6.35. Nov 18, 2015: EMBA Medical Cleared to Market Hourglass Peripheral Embolization Plug in New Zealand

7. Appendix

  • 7.1. Methodology
  • 7.2. About GlobalData
  • 7.3. Contact Us
  • 7.4. Disclaimer

List of Tables

  • Table 1: Peripheral Embolic Protection Devices - Pipeline Products by Stage of Development
  • Table 2: Peripheral Embolic Protection Devices - Pipeline Products by Segment
  • Table 3: Peripheral Embolic Protection Devices - Pipeline Products by Territory
  • Table 4: Peripheral Embolic Protection Devices - Pipeline Products by Regulatory Path
  • Table 5: Peripheral Embolic Protection Devices - Pipeline Products by Estimated Approval Date
  • Table 6: Peripheral Embolic Protection Devices - Ongoing Clinical Trials
  • Table 7: Peripheral Embolic Protection Devices Companies - Pipeline Products by Stage of Development
  • Table 8: Peripheral Embolic Protection Devices - Pipeline Products by Stage of Development
  • Table 9: Abbott Vascular Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 10: Emboshield Pro Rapid Exchange Embolic Protection System (Generation 5) - Product Status
  • Table 11: Emboshield Pro Rapid Exchange Embolic Protection System (Generation 5) - Product Description
  • Table 12: Avantec Vascular Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 13: Peripheral Embolization Device - Product Status
  • Table 14: Peripheral Embolization Device - Product Description
  • Table 15: Cardio-Flow Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 16: EmboPRO EPD - Product Status
  • Table 17: EmboPRO EPD - Product Description
  • Table 18: CardioGard Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 19: CardioGard 22 French Aortic Cannula - Product Status
  • Table 20: CardioGard 22 French Aortic Cannula - Product Description
  • Table 21: CardioGard Ltd. - Ongoing Clinical Trials Overview
  • Table 22: CardioGard 22 French Aortic Cannula - A Study to Collect Additional Information Related to the Performance of the CARDIOGARD Cannula
  • Table 23: Claret Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 24: Sentinel Cerebral Protection System - Product Status
  • Table 25: Sentinel Cerebral Protection System - Product Description
  • Table 26: Claret Medical, Inc. - Ongoing Clinical Trials Overview
  • Table 27: Sentinel Cerebral Protection System - Cerebral Protection in Transcatheter Aortic Valve Replacement - The SENTINEL Study
  • Table 28: Sentinel Cerebral Protection System - Histopathology of Embolic Debris Captured During Transcatheter Aortic Valve Replacement
  • Table 29: Sentinel Cerebral Protection System - PROTECT TAVI - Prospective Randomized Outcome Study in TAVI Patients Undergoing Periprocedural Embolic Cerebral Protection with the Claret Sentinel Device
  • Table 30: EKOS Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 31: EkoSonic Endovascular System - Product Status
  • Table 32: EkoSonic Endovascular System - Product Description
  • Table 33: EkoSonic Endovascular System - Control Unit - Product Status
  • Table 34: EkoSonic Endovascular System - Control Unit - Product Description
  • Table 35: EKOS Corporation - Ongoing Clinical Trials Overview
  • Table 36: EkoSonic Endovascular System - Accelerated Thrombolysis for Post-thrombotic Syndrome Using EKOS
  • Table 37: EkoSonic Endovascular System - Study of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in the Treatment of Acute Submassive Pulmonary Embolism
  • Table 38: EkoSonic Endovascular System - Submassive Pulmonary Embolism Experience with EKOS
  • Table 39: EkoSonic Endovascular System - Usefulness and Safety of Ultrasound-assisted Catheter-directed Thrombolysis for Submassive Pulmonary Emboli
  • Table 40: EMBA Medical Limited Pipeline Products & Ongoing Clinical Trials Overview
  • Table 41: Hourglass Peripheral Embolization Plug - Product Status
  • Table 42: Hourglass Peripheral Embolization Plug - Product Description
  • Table 43: EMBA Medical Limited - Ongoing Clinical Trials Overview
  • Table 44: Hourglass Peripheral Embolization Plug - EMBA Peripheral Embolization Device (EPED) Study
  • Table 45: Inari Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 46: FlowTriever System - Pulmonary Embolism - Product Status
  • Table 47: FlowTriever System - Pulmonary Embolism - Product Description
  • Table 48: Inari Medical, Inc. - Ongoing Clinical Trials Overview
  • Table 49: FlowTriever System - Pulmonary Embolism - FlowTriever Pulmonary Embolectomy Clinical Study
  • Table 50: Innovative Cardiovascular Solutions, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 51: Emblok Embolic Protection Catheter - Product Status
  • Table 52: Emblok Embolic Protection Catheter - Product Description
  • Table 53: Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 54: Permanently Implantable Embolic Balloon - Product Status
  • Table 55: Permanently Implantable Embolic Balloon - Product Description
  • Table 56: Keystone Heart Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 57: TriGuard Cerebral Protection Device - Product Status
  • Table 58: TriGuard Cerebral Protection Device - Product Description
  • Table 59: Keystone Heart Ltd. - Ongoing Clinical Trials Overview
  • Table 60: TriGuard Cerebral Protection Device - A Prospective, Single Arm Feasibility Study to Evaluate the Safety and Performance of the SMT Embolic Deflection Device in Patients Undergoing Transcatheter Aortic Valve Replacement (TAVR)
  • Table 61: TriGuard Cerebral Protection Device - A Randomized Evaluation of the TriGuard Embolic Deflection Device to Reduce the Impact of Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation
  • Table 62: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 63: SilverHawk With SpiderFX Embolic Protection Device - Product Status
  • Table 64: SilverHawk With SpiderFX Embolic Protection Device - Product Description
  • Table 65: Metactive Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 66: Blockstent Microcatheter - Product Status
  • Table 67: Blockstent Microcatheter - Product Description
  • Table 68: MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 69: Aortic Embolic Protection Device - Product Status
  • Table 70: Aortic Embolic Protection Device - Product Description
  • Table 71: Neurosonix Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 72: Protection Collar - Product Status
  • Table 73: Protection Collar - Product Description
  • Table 74: Trinity College Dublin Pipeline Products & Ongoing Clinical Trials Overview
  • Table 75: Transcatheter Device - Atherosclerotic Plaque - Product Status
  • Table 76: Transcatheter Device - Atherosclerotic Plaque - Product Description
  • Table 77: University of Minnesota Pipeline Products & Ongoing Clinical Trials Overview
  • Table 78: Embolic Protection Device - Product Status
  • Table 79: Embolic Protection Device - Product Description
  • Table 80: University of Toledo Pipeline Products & Ongoing Clinical Trials Overview
  • Table 81: Minimally Invasive Thrombectomy Device - Product Status
  • Table 82: Minimally Invasive Thrombectomy Device - Product Description
  • Table 83: Glossary

List of Figures

  • Figure 1: Peripheral Embolic Protection Devices - Pipeline Products by Stage of Development
  • Figure 2: Peripheral Embolic Protection Devices - Pipeline Products by Segment
  • Figure 3: Peripheral Embolic Protection Devices - Pipeline Products by Territory
  • Figure 4: Peripheral Embolic Protection Devices - Pipeline Products by Regulatory Path
  • Figure 5: Peripheral Embolic Protection Devices - Pipeline Products by Estimated Approval Date
  • Figure 6: Peripheral Embolic Protection Devices - Ongoing Clinical Trials
Back to Top